Johnson & Johnson Price to Sales Ratio 2012-2026 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of September 08, 2026 is .
| Johnson & Johnson P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-08 | 269.12 | 6.69 | |
| 2026-06-30 | 252.72 | $40.20 | 6.29 |
| 2026-03-31 | 241.82 | $39.65 | 6.10 |
| 2025-12-31 | 203.65 | $38.84 | 5.24 |
| 2025-09-30 | 181.32 | $38.00 | 4.77 |
| 2025-06-30 | 148.28 | $37.37 | 3.97 |
| 2025-03-31 | 159.62 | $36.83 | 4.33 |
| 2024-12-31 | 138.09 | $36.59 | 3.77 |
| 2024-09-30 | 153.51 | $35.68 | 4.30 |
| 2024-06-30 | 137.41 | $34.80 | 3.95 |
| 2024-03-31 | 147.53 | $33.72 | 4.37 |
| 2023-12-31 | 145.07 | $32.94 | 4.40 |
| 2023-09-30 | 143.01 | $29.30 | 4.88 |
| 2023-06-30 | 150.89 | $28.44 | 5.31 |
| 2023-03-31 | 140.24 | $29.25 | 4.79 |
| 2022-12-31 | 158.68 | $30.01 | 5.29 |
| 2022-09-30 | 145.80 | $28.96 | 5.04 |
| 2022-06-30 | 157.38 | $30.17 | 5.22 |
| 2022-03-31 | 156.13 | $29.89 | 5.22 |
| 2021-12-31 | 149.74 | $29.46 | 5.08 |
| 2021-09-30 | 140.44 | $34.22 | 4.10 |
| 2021-06-30 | 142.41 | $33.39 | 4.27 |
| 2021-03-31 | 141.19 | $31.54 | 4.48 |
| 2020-12-31 | 134.37 | $30.94 | 4.34 |
| 2020-09-30 | 126.23 | $30.25 | 4.17 |
| 2020-06-30 | 118.45 | $30.12 | 3.93 |
| 2020-03-31 | 109.69 | $30.88 | 3.55 |
| 2019-12-31 | 121.25 | $30.55 | 3.97 |
| 2019-09-30 | 106.80 | $30.30 | 3.53 |
| 2019-06-30 | 114.12 | $29.99 | 3.80 |
| 2019-03-31 | 113.76 | $30.01 | 3.79 |
| 2018-12-31 | 104.32 | $29.91 | 3.49 |
| 2018-09-30 | 110.99 | $29.79 | 3.73 |
| 2018-06-30 | 96.82 | $29.51 | 3.28 |
| 2018-03-31 | 101.51 | $28.73 | 3.53 |
| 2017-12-31 | 109.97 | $27.86 | 3.95 |
| 2017-09-30 | 101.70 | $26.99 | 3.77 |
| 2017-06-30 | 102.83 | $26.21 | 3.92 |
| 2017-03-31 | 96.18 | $25.95 | 3.71 |
| 2016-12-31 | 88.38 | $25.74 | 3.43 |
| 2016-09-30 | 90.00 | $25.58 | 3.52 |
| 2016-06-30 | 91.80 | $25.27 | 3.63 |
| 2016-03-31 | 81.31 | $24.98 | 3.25 |
| 2015-12-31 | 76.63 | $24.90 | 3.08 |
| 2015-09-30 | 69.13 | $24.94 | 2.77 |
| 2015-06-30 | 71.63 | $25.29 | 2.83 |
| 2015-03-31 | 73.40 | $25.75 | 2.85 |
| 2014-12-31 | 75.77 | $25.91 | 2.92 |
| 2014-09-30 | 76.73 | $25.91 | 2.96 |
| 2014-06-30 | 74.81 | $25.56 | 2.93 |
| 2014-03-31 | 69.75 | $24.96 | 2.79 |
| 2013-12-31 | 64.57 | $24.78 | 2.61 |
| 2013-09-30 | 60.69 | $24.65 | 2.46 |
| 2013-06-30 | 59.66 | $24.60 | 2.43 |
| 2013-03-31 | 56.23 | $24.30 | 2.31 |
| 2012-12-31 | 47.96 | $24.00 | 2.00 |
| 2012-09-30 | 46.74 | $23.61 | 1.98 |
| 2012-06-30 | 45.41 | $23.32 | 1.95 |
| 2012-03-31 | 43.91 | $23.40 | 1.88 |
| 2011-12-31 | 43.27 | $23.42 | 1.85 |
| 2011-09-30 | 41.64 | $23.17 | 1.80 |
| 2011-06-30 | 43.10 | $22.79 | 1.89 |
| 2011-03-31 | 38.06 | $22.30 | 1.71 |
| 2010-12-31 | 39.38 | $22.06 | 1.79 |
| 2010-09-30 | 39.11 | $22.38 | 1.75 |
| 2010-06-30 | 36.93 | $22.40 | 1.65 |
| 2010-03-31 | 40.40 | $22.40 | 1.80 |
| 2009-12-31 | 39.61 | $22.20 | 1.78 |
| 2009-09-30 | 37.15 | $21.62 | 1.72 |
| 2009-06-30 | 34.38 | $21.84 | 1.57 |
| 2009-03-31 | 31.56 | $22.15 | 1.42 |
| 2008-12-31 | 35.60 | $22.41 | 1.59 |
| 2008-09-30 | 40.88 | $22.54 | 1.81 |
| 2008-06-30 | 37.72 | $22.05 | 1.71 |
| 2008-03-31 | 37.77 | $21.45 | 1.76 |
| 2007-12-31 | 38.57 | $20.94 | 1.84 |
| 2007-09-30 | 37.76 | $20.08 | 1.88 |
| 2007-06-30 | 35.18 | $19.45 | 1.81 |
| 2007-03-31 | 34.18 | $18.76 | 1.82 |
| 2006-12-31 | 37.23 | $17.96 | 2.07 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $663.276B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |